CURBSIDE CONSULTATION IN IBD. 49 CLINICAL QUESTIONS. 3RD EDITION

Dedication
About the Editors
Contributing Authors
Preface
Introduction
• Section I Diagnosis and Prognosis
Question 1 How Can We Assess Prognosis in Crohn’s Disease?
Question 2 How Do You Evaluate and Treat Mid-¬Proximal Small Bowel Crohn’s Disease?
Question 3 What Is Your First-¬Line Approach to the Diagnosis and Treatment of Patients With Perianal Crohn’s Disease?
Question 4 What Is the Updated Role of Capsule Endoscopy in IBD?
Question 5 How Should We Be Using Fecal Markers in Our Patients?
Question 6 What Endpoints Should We Aim for in IBD Medical Therapy?
• Section II Medical Treatment
Question 7 When Should We Be Using 5-¬Aminosalicylic Acids in IBD? How Do You Optimize Their Use?
Question 8 What Is Ste¬roid Dependence and How Is It Managed?
Question 9 What Are the New Approaches to Using and Minimizing Ste¬roids?
Question 10 Should You Use Concomitant Immunomodulators With Biological Therapies in IBD?
Question 11 If, When, and How Should Thiopurines Be Used in IBD?
Question 12 How Should Methotrexate Be Used in IBD?
Question 13 What Is the Evolving Role of Calcineurin Inhibitors in IBD?
Question 14 What Preparations Should Occur Before Initiating Biologic Therapy?
Question 15 Where Should Anti-¬Integrin Therapy Be Placed in the Therapeutic Algorithm for Crohn’s Disease and Ulcerative Colitis?
Question 16 Where Should Anti–Interleukin 23 Therapy Be Placed in the Therapeutic Algorithm for Crohn’s Disease and Ulcerative Colitis?
Question 17 What Should Clinicians and Patients Know About Biosimilars?
Question 18 What Are Janus Kinase Inhibitors and When Should They Be Used in IBD?
Question 19 What Is the Approach for Loss of Response to Biological Therapy?
Question 20 How Should Proactive Therapeutic Drug Monitoring Be Considered in Our Patients?
Question 21 What Are the Risks of Biologic Therapies and How Do You Communicate Them to Patients?
Question 22 When Should We Consider Deescalation of Therapy?
Question 23 Can You Restart a Biological Therapy ¬After a Drug Holiday? How Do You Do This?
Question 24 How Can I Get My Patients With IBD the Therapy They Need?
• Section III Alternative Treatments
Question 25 What Is the Role of Probiotics for Patients With IBD?
Question 26 What Do I Tell My Patient With IBD Who Is Asking About Cannabis as Therapy?
• Section IV Special Populations
Question 27 How Do You Treat Pouchitis and What Do You Do for Recurrent or Refractory Pouchitis?
Question 28 My Patient With IBD Is Complaining of Joint Pain. What Should I Do?
Question 29 What Are the Diagnostic and Therapeutic Approaches to the Patient With IBD With Pain?
Question 30 My Patient on Tumor Necrosis ¬Factor Alpha Therapy Has a Rash. What Should I Do?
Question 31 What Is the Approach to Primary Sclerosing Cholangitis in IBD?
Question 32 What Is the Best Medical Therapy for IBD in Older Patients?
Question 33 How Should Clinicians Treat Men With IBD? What Are the Unique Concerns?
Question 34 What Is the Updated Approach to IBD Medical Therapy in Pregnancy and What Is Known About Neonatal Outcomes in Babies Born
to Mothers With IBD?
• Section V Infection and Malignancy Prevention
Question 35 How Do You ¬Handle a Patient With IBD With Clostridioides difficile Infection?
Question 36 How Do You Treat IBD in the Setting of Current or Previous Cancer?
Question 37 What Is the Updated Approach to Surveillance and Colorectal Cancer Prevention in IBD?
• Section VI Surgical Treatment
Question 38 What Is the Appropriate Evaluation of the Preoperative Patient With IBD? (Malnutrition, Steroids, Smoking)
Question 39 My Patient With Crohn’s Disease Has an Ileal Abscess. What Is the Appropriate Management and Timing of Medical and Surgical Therapies?
Question 40 What Is the Updated Approach to Monitoring and Prevention in a Patient With Crohn’s Disease After an Ileocecectomy and Primary Anastomosis?
Question 41 How Does Perioperative Immune Suppression Affect Surgical Outcomes in IBD?
Question 42 Does the Type of Surgical Anastomosis (End-¬to-¬End Versus Side-¬to--Side) Make a Difference in Long-¬Term Crohn’s Disease Outcomes and in Recurrence?
• Section VII Health Maintenance
Question 43 What Is the Most Successful Strategy to Promote Smoking Cessation in Patients With Crohn’s Disease?
Question 44 Which Vaccines Should Patients With IBD Receive?
Question 45 How Can Gastroenterologists Address IBD-Related Health Maintenance in Clinical Practice?
Question 46 How Should We Screen Our Patients With IBD for Depression and Anxiety?
Question 47 What Is the Role of Diet in the Treatment of IBD and How Do I Discuss This With My Patients?
Question 48 What Advice Should I Give the Patient With IBD Who Is Traveling?
Question 49 How Should We Approach the Diagnosis and Evaluation of Sexual Dysfunction in Patients With IBD?
Financial Disclosures
Index

Newly updated with the latest information on inflammatory bowel disease, Curbside Consultation in IBD: 49 Clinical Questions, Third Edition contains brief, practical, and evidence-based answers to the most frequently asked questions that are posed during a “curbside consultation” between surgical colleagues.

Drs. David T. Rubin, Sonia Friedman, and Francis A. Farraye are joined by an expert group of contributors, offering advice, preferences, and opinions on tough clinical questions commonly associated with IBD. With a unique Q&A format, this text provides quick access to current information. Numerous images, diagrams, and references are included to better illustrate IBD.


Some of the questions answered inside the Third Edition include:
• What are the new approaches to using and minimizing steroids?
• What is the evolving role of calcineurin inhibitors in IBD?
• Where should anti-IL-23 therapy be placed in the therapeutic algorithm for Crohn’s disease and ulcerative colitis?
• What should the clinicians and patients know about biosimilars?
• What are JAK inhibitors? And when should they be used in IBD?
• What is the approach to loss of response to biological therapy?
• How should we screen our patients with IBD for depression and anxiety?

With information basic enough for trainees and expert practical advice that even high-volume clinicians will appreciate, Curbside Consultation in IBD: 49 Clinical Questions, Third Edition is a must-have. Gastroenterologists, surgeons, IBD nurses and advanced practice providers, and medical and surgical trainees at all levels will benefit from the user-friendly format and up-to-date advice for complicated cases.